About Us
Real-time Quotes & News
Market Analysis
Trading Platform
Terms
Promotion
FAQ
Contact
繁
简
EN
繁
简
EN
Promotion
FAQ
Contact
Open Account
Contact Us

Merck (MRK.N) said China's National Medical Products Administration (NMPA) approved a subcutaneous formulation of its PD‑1 inhibitor pembrolizumab for 19 solid‑tumor indications, making it the first and currently only PD‑1 inhibitor with an approved

2026-09-29

Merck (MRK.N) said China's National Medical Products Administration (NMPA) approved a subcutaneous formulation of its PD‑1 inhibitor pembrolizumab for 19 solid‑tumor indications, making it the first and currently only PD‑1 inhibitor with an approved subcutaneous formulation in China.

Other News
2026-09-29

On Sept. 29 CHINA STATE PLANNER said it will guide localities in a new round of pilots to deepen integration between advanced manufacturing and modern services. Since 2020 it has run two national pilot rounds that selected regions and firms and deliv

On Sept. 29 CHINA STATE PLANNER said it will guide localities in a new round of pilots to deepen integration between advanced manufacturing and modern services. Since 2020 it has run two national pilot rounds that selected regions and firms and delivered some innovation breakthroughs. Working with other departments and focusing on a set of “three anchors,” the agency said it will promote a tech–industry–finance virtuous cycle, address supply‑chain bottlenecks, and explore market‑based mechanisms for allocating technology inputs and for distributing proceeds from technology commercialization.
2026-09-29

Manus released version 2.0 for overseas users and launched Cue, a smart assistant designed for personal life scenarios.

Manus released version 2.0 for overseas users and launched Cue, a smart assistant designed for personal life scenarios.
Open Account
Demo Account
Contact Us
About Us Real-time Quotes & News Market Analysis
 Trading Platform Market Analysis Promotion Terms Promotion FAQ Contact
Copyright © 2026 Aspire Global Company Limited. All Rights Reserved.
Terms of Use and Privacy
Disclaimer

Disclaimer: ASPIRE is not responsible for the content of any analysis, advice, comment, suggestion, research report or market data in this website and links to third-party websites or resources. All the information mentioned above only represents the view of corresponding author. ASPIRE cannot and does not warrant the accuracy, validity, timeliness or completeness of any such information. You should conduct individual assessments and other proper research to make their investment decisions. The materials and information contained in this website are provided for reference only and do not constitute or form an offer, invitation, solicitation or investment advice or recommendation to acquire or dispose of any investment products or services. The price of any financial instruments described in this website may fall as well as rise. Past performance should not be taken as an indication of future performance. The risk disclosure statements do not purport to disclose or discuss all of the risks and other significant aspects of any financial instruments mentioned in this website. You should make your own appraisal of the risk and should consult to the extent necessary your own legal, tax, financial or other professional advisers in respect of any financial instruments mentioned in this website prior to entering into any transaction.

Risk Warning: Leveraged Precious Metals trading on margin carries significant risks and is not suitable for all investors. Please be sure to make investments within your own tolerance after fully understand the risks involved.

Registered & Business Address: Room 1905-1906, 19/F, Eastern Commercial Centre, 395-399 Hennessy Road, Hong Kong

Aspire Global Company Limited is not available to provide services for the residents of certain jurisdictions such as Afghanistan, the United States of America, the Islamic Republic of Iran, North Korean.